was present in 59% of the patients; recurrent infections during childhood were common; 20% required amigdalectomy. One patient suffered rheumatic fever; one patient had not been effectively immunized after repeated hepatitis vaccines; and another had defective CD4 and suffered recurrent pneumo coccal infections.
It would be surprising if these illnesses did not share a common root in the immune system. Schmidt (2011) underlined rising prevalence rates of auto immunity and dis cussed causes. I believe that this trend is rele vant in general to immune disorders because of different reactions within the same scope of lymphocyte dysfunction in response to our new aggressive environment. Rudel et al. (2011) is based on the concentration of DEHP metabolites-before correcting for creatinine levels. With little more than a sentence, Rudel et al. dismissed the accepted practice of correcting for crea tinine levels to account for the substantial variability in an individual's urine output. They suggested that such adjustment may "bias associations between urine metabo lite concentrations and age or sex" (Rudel et al. 2011 ) without explaining that the correction is widely used in urinary bio monitoring (by the Centers for Disease Control and most others) to improve the comparability of meas ure ments across individuals.
To their credit, Rudel et al. (2011) did conduct a compari son of the creatinine adjusted levels of DEHP metabolites and found no statistically significant difference in the mean levels of two of the three metabo lites before and after dietary intervention. The authors did not report the change in the adjusted levels of the third metabolite in the article.
The authors also did not address the variability in preintervention levels among the study participants. The presence of two individuals with very high metabolite levels clearly skewed the mean value upward and, consequently, exaggerated the significance of the intervention. Although Table 2 Steven Risotto, representing phthalate manufacturers for the American Chemistry Council (ACC), commented on our study that found a 3day diet with limited food packaging reduced participants' average bis(2ethyl hexyl) phthalate (DEHP) expo sure by > 50% (Rudel et al. 2011 ).
Risotto's statement that creatinine adjust ment by normalization is accepted practice is misleading. Creatinine normali za tion is appropriate in a longitudinal study if the daily creatinine excretion of the partici pants remains approximately constant. That assumption is not reasonable in a dietary intervention because shortterm changes in diet can strongly influence creatinine levels (Kesteloot and Joossens 1993) . In our article (Rudel et al. 2011) , we addressed urinary dilution by including creatinine as a vari able in the mixedeffects model that estimates exposure reduction from the intervention, as currently recommended by researchers at the Centers for Disease Control and Prevention (Barr et al. 2005) . Our analysis showed sig nificant decreases of 53-56% in the three DEHP metabo lites. Because creatinine nor malization is common, we also included nor malized results. Creatinine levels dropped significantly during the intervention, indicat ing that creatinine normalization artificially reduced the observed change. Nonetheless, results showed a 42-45% decrease in all three DEHP metabolites; the decrease was statistically significant for the most abun dant metabolite, MEHHP (mono(2ethyl 5hydroxy hexyl) phthalate).
Risotto also questions whether DEHP reductions are attributable to two individu als with high initial exposures. However, we reported the decreases in geometric means, which are not strongly influenced by a few high values. After removing these two participants, we still observed decreases of 37-42% in the geometric means of DEHP metabolites, and reductions in the two most abundant metabolites remain statistically sig nificant. Removing participants with high pre intervention exposures is appropriate if an unknown exposure may have covaried with the inter vention, but because the two highest exposures were in different families, such confounding seems unlikely.
As to why DEHP metabolite levels dropped during the intervention but did not increase significantly after the interven tion-as discussed in detail in our article (Rudel et al. 2011 )-the discrepancy may be attributable to the differentlength "washout periods" (~ 48 hr between the beginning of the intervention and the first intervention urine sample, and ~ 36 hr between when participants resumed their regular diet and the first post intervention urine sample).
Risotto questions the public health signifi cance of our observed reduction in DEHP exposure. However, DEHP exposure levels in our study (Rudel et al. 2011 )-and in the U.S. population-are similar to or higher than those recently reported to exceed health guidelines. Koch et al. (2011) found that 5 of 108 children studied had daily DEHP intakes in excess of the current U.S. Environmental Protection Agency reference dose, and 25% exceeded the tolerable daily intake for cumulative exposure to several anti androgenic phthalates that act additively. This risk assessment contradicts the mis leading ACC press release about our study, which claimed "consumer exposure to BPA [bisphenol A] and DEHP, from all sources, is up to 1,000 times lower than government established safe exposure levels" (ACC 2011). This statement suggested to reporters that consumer exposures are much lower than government health guidelines, when in fact a substantial percentage of DEHP exposures are above guidelines.
Although our findings (Rudel et al. 2011) indicate that food packaging was a major source of DEHP in early 2010, we are encouraged by Risotto's news that the indus try believes DEHP is no longer used in food packaging. If manufacturers provided com prehensive information about chemicals in products, scientists, regulators, and consumers would not have to resort to expensive studies to understand potential risks and opportu nities for mitigation. Not knowing the new packaging formulations, we cannot evaluate them. We hope manufacturers have carefully tested the DEHP substitutes for endocrine disruption and other safety concerns.
